Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Despite Pfizer management's cost-cutting and a large drug pipeline, revenue growth remains uncertain. Click here to read an ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Pfizer CEO Dr. Albert Bourla speaks to CNN’s Meg Tirrell about pushing past vaccine skepticism to work with the Trump ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...